<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antibodies to Ro/SSA are found in patients with <z:hpo ids='HP_0011011'>subacute</z:hpo> <z:e sem="disease" ids="C0024137" disease_type="Disease or Syndrome" abbrv="">cutaneous lupus erythematosus</z:e> (SCLE), <z:hpo ids='HP_0004431'>complement deficiency</z:hpo> <z:e sem="disease" ids="C0409974" disease_type="Disease or Syndrome" abbrv="">lupus erythematosus</z:e>, <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), <z:e sem="disease" ids="C0409979" disease_type="Disease or Syndrome" abbrv="">neonatal lupus erythematosus</z:e>, and <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sjögren</z:e> syndrome (SS) </plain></SENT>
<SENT sid="1" pm="."><plain>Most studies describing the cutaneous pathology associated with anti-Ro antibodies have been of patients with SCLE </plain></SENT>
<SENT sid="2" pm="."><plain>Over a 42-month period, we encountered skin biopsy specimens from 23 anti-Ro-positive patients who did not have SCLE: 15 had SLE variably manifesting as SCLE-like <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rashes</z:e>; malar <z:hpo ids='HP_0010783'>erythema</z:hpo>; a <z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatomyositis</z:e>-like <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e>; <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> involving cutaneous, cardiac, peripheral, and central <z:mp ids='MP_0008912'>nervous</z:mp> systems; <z:e sem="disease" ids="C0877013" disease_type="Disease or Syndrome" abbrv="">restrictive pulmonary disease</z:e>; <z:hpo ids='HP_0100539'>periorbital edema</z:hpo>; and <z:hpo ids='HP_0100614'>myositis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Two patients had primary <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sjögren</z:e> syndrome, one had primary <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome, and two had <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo>; <z:hpo ids='HP_0000001'>all</z:hpo> five had clinical evidence of cutaneous vasculopathy encompassing livedo, perniosis, and palpable <z:hpo ids='HP_0000979'>purpura</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Three additional patients presented with folliculocentric <z:hpo ids='HP_0000979'>purpura</z:hpo> without other stigmata to permit classification as a specific <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In the SLE patients, biopsy specimens of photodistributed eruptions showed an interface <z:hpo ids='HP_0000964'>dermatitis</z:hpo> accompanied by superficial vascular plexus density reduction </plain></SENT>
<SENT sid="6" pm="."><plain>Vasculopathic reactions in patients with and without SLE comprised neutrophilic, lymphocytic, or pauciinflammatory thrombogenic subtypes </plain></SENT>
<SENT sid="7" pm="."><plain>Although at times a marker of SCLE, the identification of anti-Ro antibodies may isolate a subset of patients at higher risk of multiorgan vasculopathy, <z:hpo ids='HP_0100614'>myositis</z:hpo>, and progressive <z:e sem="disease" ids="C0024115" disease_type="Disease or Syndrome" abbrv="">pulmonary disease</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>We postulate that many of the features seen in these patients reflect the sequelae of antibody mediated endothelial cell injury </plain></SENT>
</text></document>